This page uses javascripts, but your browser is not currently supporting JavaScripts. Please turn ON scripting in your web browser. Skip to Content

Home What is Buprenorphine? Buprenorphine Products DATA Physician Locator DATA 2000 FAQs Links En Español Physician Waiver Qualifications Waiver Notification Form Ongoing Web-based Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports To check on a physician's waivered status, please call the Buprenorphine Information Center at 1.866.287.2728. Nurses Guide to Buprenorphine Online Buprenorphine Course for Counselors

New Federal Law Increases Patient Limits

The Office of National Drug Control Policy Reauthorization Act of 2006 (ONDCPRA) modifies the restriction on the number of patients a physician authorized under the Drug Addiction Treatment Act of 2000 (DATA 2000) may treat subject to the following conditions:
  1. Physicians must currently be authorized under DATA 2000.

  2. Physicians must have submitted the notification for initial authorization at least 1 year ago.

  3. Physicians must submit a second notification that conveys the need and intent to treat up to 100 patients (items 6 and 10) and certifies their necessary qualifying criteria (item 8) and their capacity to refer patients for appropriate counseling and other appropriate ancillary services (item 9), and they must sign and date the form.
For second notifications:
  • If you have an e-mail address, you can use this on-line link to submit your notification.
  • If you do NOT have an e-mail address, you can use this HTML link to access a form pre-filled with information from your original waiver notification.
  • Use this PDF link to access a blank form to increase patient limits.

SAMHSA/CSAT will formally acknowledge your submission of the second notification by letter; however, unless you are notified of the contrary, the "good faith" submission of the second notification permits treatment of up to 100 patients.

To obtain additional information regarding this matter, contact the CSAT Buprenorphine Information Center at 866-BUP-CSAT (866-287-2728), or by e-mail at


Go to U.S. Department of Health and Human Services
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services |

* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.

Go to Division of Pharmacologic Therapies